Eli Lilly’s (LLY) new marketing campaign focuses on weight stigma and healthy body image.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The pharmaceutical company has unveiled a short one-minute film called “My Focus” that is about the stigma that often comes with being overweight. The latest short film builds on previous short films from Eli Lilly called “Big Night” and “Shame” that also emphasized the importance of healthy body image.
Specifically, the new video spotlights societal shame that impacts many people with overweight and obesity issues. Eli Lilly says its goal with the new “My Focus” film is to “reframe how obesity is talked about in culture” and to push back against societal stigma that focuses on people’s outward appearance.
Weight-Loss Drug Wars
“We believe obesity is a matter of health, not weight or appearance, and this film reflects our commitment to challenging weight-obsessed cultural narratives and championing health-centered conversations about obesity,” says Eli Lilly about its latest video.
The new marketing campaign comes as competition heats up in the market for weight-loss drugs. Eli Lilly’s main rival, Novo Nordisk (NVO), just released its first weight-loss pill and it has gotten off to a strong start. Eli Lilly’s own weight-loss pill is expected to be released this summer.
Is LLY Stock a Buy?
The stock of Eli Lilly has a consensus Strong Buy rating among 20 Wall Street analysts. That rating is based on 18 Buy and two Hold recommendations issued in the last three months. The average LLY price target of $1,191.37 implies 12.15% upside from current levels.
